ArticleBMC infectious diseases2026
Predictive value of macrophage inflammatory protein 3β in the risk of death in sepsis patients.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aims to explore the predictive value of macrophage inflammatory protein 3β (MIP-3β) for mortality risk in sepsis patients.
methods177 sepsis patients visited the emergency medicine department of Beijing Chaoyang Hospital between October 2020 and April 2021. Within 1 h of admission, serum levels of WBC (white blood cell), PLT (platelet), TBIL (total bilirubin), PCT (procalcitonin), CRP (C-reactive protein), and MIP-3β were measured, and patients were assessed with organ failure scores—SOFA (Sequential Organ Failure Assessment) and APACHE II (Acute physiology and chronic health evaluation) scores. Logistic regression was used to predict independent risk factors for 28-day mortality, and Receiver Operating Characteristic (ROC)curves were used to assess predictive value. The categorical net reclassification improvement (NRI) was calculated to assess the incremental predictive value of adding MIP-3β to the SOFA score.
resultsMIP-3β (pg/mL), SOFA, and APACHE II scores were significantly higher in non-survivors compared to survivors (P < 0.05). The logistic regression analysis revealed that the MIP-3β, SOFA, and APACHE II scores were independent risk factors for 28-day mortality (P < 0.05) in sepsis patients. The area under the ROC curve (AUC) for the MIP-3β was 0.635 (sensitivity 0.573, specificity 0.679, critical value 93.43), indicating modest predictive value, lower than SOFA score 0.839 (sensitivity 0.573, specificity 0.962, critical value 7.5, Z = 3.446, P = 0.0006) and APACHE II score 0.773 (sensitivity 0.556, specificity 0.925, critical value 21.5, Z = 2.304, P = 0.0212); however, the combined prediction using MIP-3β and SOFA scores (AUC area 0.86, sensitivity 0.637, specificity 0.981, Z = 4.552, P < 0.0001) had higher AUC area, sensitivity, and specificity than MIP-3β alone (Table 3). Furthermore, adding MIP-3β to the SOFA score yielded a significant categorical NRI of 0.062 (95% CI: 0.023–0.107, P < 0.01), calculated using pre-specified risk categories of < 10%, 10–50%, and > 50% for 28-day mortality risk, indicating improved risk stratification.
conclusionsMIP-3β is an independent risk factor for 28-day mortality in sepsis, with higher levels associated with increased risk of death. While MIP-3β alone has modest predictive value, its combination with the SOFA score significantly improves mortality prediction, highlighting its potential role as a complementary biomarker for early risk stratification in sepsis. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.